Median Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)
Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2020, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2020 – Publication will be done on October 14, 2020 after the close of trading.
Disclosure of total number of voting rights and number of shares in the capital as of July 31st, 2020, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
To download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]